ISPC - iSpecimen nearly doubles after announcing contract for COVID-19 research

Microcap health tech company iSpecimen (ISPC +97.6%) has nearly doubled in value to reach a post-IPO high on above-average volume. In the pre-market, the operator of iSpecimen Marketplace announced that the U.S. government and some private researchers contracted the company to deliver human biospecimens for advanced research on COVID-19. "We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they're focusing on," CEO Christopher Ianelli noted. The company also announced that it obtained the services of a new partner to supply the researchers with swabs and biofluid samples that have undergone genetic sequencing and are categorized based on the COVID-19 variant. Nearly 64.4M of iSpecimen (NASDAQ:ISPC) shares have changed hands so far, compared to the 65-day average volume of ~67.2K shares. The company revenue for the first nine months of 2021 has surged ~57% YoY to $8.6M.

For further details see:

iSpecimen nearly doubles after announcing contract for COVID-19 research